➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Medtronic
McKesson
Boehringer Ingelheim
Dow

Last Updated: July 9, 2020

DrugPatentWatch Database Preview

Human fibrinogen, human thrombin - Biologic Drug Details


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for human fibrinogen, human thrombin
Tradenames:1
Patents:1
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for human fibrinogen, human thrombin
Recent Clinical Trials for human fibrinogen, human thrombin

Identify potential brand extensions & biosimilar entrants

SponsorPhase
ZonMw: The Netherlands Organisation for Health Research and DevelopmentPhase 3
R.J.H. CustersPhase 3
University of MarylandPhase 3

See all human fibrinogen, human thrombin clinical trials

Patent Text Search: US Patents for human fibrinogen, human thrombin

These patents were identified by searching patent claims

Supplementary Protection Certificates for human fibrinogen, human thrombin

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2001 Austria   Start Trial PRODUCT NAME: RECOMBINANTES HUMANES OSTEOGENES PROTEIN-1 (OP 1); REGISTRATION NO/DATE: EU/1/01/179/001 20010517
2001 00033 Denmark   Start Trial PRODUCT NAME: REKOMBINANT HUMANT OSTEOGENT PROTEIN-1: BMP-7; REG. NO/DATE: EU/1/01/179/001 20010517
2016000049 Germany   Start Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
199011 Germany   Start Trial PRODUCT NAME: KRISTALLE, ENTHALTEND ASP B28 HUMAN-INSULIN UND PROTAMIN; REGISTRATION NO/DATE: EU/1/00/142/001-008 20000801
C0024 France   Start Trial PRODUCT NAME: NATALIZUMAB,ANTICORPS MONOCLONAL HUMANISE ANTI-INTEGRINE ALPHA-4; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
C/GB01/022 United Kingdom   Start Trial PRODUCT NAME: RECOMBINANT HUMAN LUTEINISING HORMONE; REGISTERED: UK EU/1/00/155/001-006 20001129
2015 00043 Denmark   Start Trial PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Merck
Colorcon
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.